A Single Center, Open Label Prospective Observational Pilot Study to Evaluate the Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)

To assess the effects of a daily single oral dose of 20 mg tasimelteon compared to baseline on events of dream enactment on patients with REM Behavior Disorder, as measured by a daily log.
To assess the effects of 20 mg tasimelteon compared to baseline on insomnia= symptoms, as measured by validated questionnaires (Insomnia Severity Index [ISI], Pittsburgh Sleep Quality Inventory [PSQI], Epworth Sleepiness Scale [ESS], Clinical Global Impression of Change Scale (CGI-C), Patient Global Impression of Change Scale (PGI-C)) as well as rest/activity pattern from actigraphy.
To assess the effects of 20 mg tasimelteon on patients who have a reduced or aberrant melatonin secretion compared to normal secretion by measuring salivary DLMO at baseline and correlating with the degree of change in RBD symptoms by end of the study.
To assess for any role a patient's unique genome may play in their response to tasimelteon; obtained via whole genome sequencing.
To assess the safety and tolerability of a daily single oral dose of 20 mg tasimelteon.

Start Date30 Sep 2023

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

[+1]

NCT05572281 / CompletedPhase 1

An Open-Label, Two-Period, Randomized, Single Oral Dose, Crossover Study to Evaluate the Bioequivalence of Tasimelteon Capsule Formulation Relative to Tasimelteon Liquid Suspension Formulation in Healthy Volunteers

This is a single center, two-period, randomized study to evaluate the bioequivalence of a single dose of tasimelteon capsule formulation relative to a single dose of liquid suspension formation in healthy volunteers.

Start Date18 May 2022

Sponsor / Collaborator

Vanda Pharmaceuticals, Inc.

NCT05361707 / RecruitingPhase 3

A Study to Evaluate the Efficacy and Safety of Tasimelteon in Treating Sleep Disturbances in Individuals With Autism Spectrum Disorder

This is a multicenter, open-label study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon in treating sleep disturbances in pediatric and adult participants with ASD.

Start Date28 Jul 2021

Sponsor / Collaborator

Vanda Pharmaceuticals, Inc.

100 Clinical Results associated with Tasimelteon

100 Translational Medicine associated with Tasimelteon

100 Patents (Medical) associated with Tasimelteon

120

Literatures (Medical) associated with Tasimelteon

01 Jan 2024·Journal of ethnopharmacology

Anti-inflammatory effects of TNF-α and ASK1 inhibitory compounds isolated from Schkuhria pinnata used for the treatment of dermatitis

Article

Author: Rumbero Sánchez, Ángel ; Sánchez Sánchez-Corral, Javier ; Hervás Povo, Belén ; Apaza Ticona, Luis

ETHNO-PHARMACOLOGICAL RELEVANCE:

The Andean Schkuhria pinnata species commonly known as 'Canchalagua' is used as an infusion in Andean countries to treat various anti-inflammatory and skin-related pathologies.

AIM OF THE STUDY:

This study determined the anti-inflammatory activity of the aqueous extract from Schkuhria pinnata, identified compounds with high biological activity and performed a structure-activity relationship analysis to determine their binding mechanism.

MATERIALS AND METHODS:

A bio-guided isolation of the active compounds of Schkuhria pinnata was carried out by selecting the most active sub-extracts and fractions to test their anti-inflammatory activity against the ASK1 and TNF-α cytokines.

RESULTS:

Three compounds were obtained, and their structures were elucidated by nuclear magnetic resonance. The compounds were (3R,4R)-4-(3,4-dimethoxybenzyl)-3-(4-hydroxy-3-methoxybenzyl) dihydrofuran-2(3H)-one (1), N-[2,3-dihydro-1,3-dimethyl-6-[(2R)-2-methyl-1-piperazinyl]-2-oxo-1H-benzimidazol-5-yl]-2-methoxybenzamide (2), and N-hydroxy-1-cyclopentene-1-carboxamide (3). Regarding their anti-inflammatory activity, the three compounds inhibited the TNF-α and ASK1 cytokines, however, compound 2 was the most active, with an IC₅₀ of 19.08 and 8.94 nM, respectively.

CONCLUSION:

The anti-inflammatory activity of the aqueous extract of Schkuhria pinnata was evaluated, followed by the isolation of three compounds and the study of their pharmacological activity. The three compounds have been shown as promising treatment against dermatitis, confirming at the same time their traditional use.

01 Sep 2023·Food science & nutrition

Sex differences in vitamin D and behavioral profiles among children with allergic diseases.

Article

Author: Guo, Mindy Ming-Huey ; Kuo, Ho-Chang ; Li, Chia-Jung ; Chang, Ling-Sai ; Wang, Liang-Jen

Previous studies have suggested that vitamin D has a protective effect on allergic diseases, while an individual's sex may have a moderating effect on the relationship between vitamin D and allergic-related immunity. This study aimed to determine the role of vitamin D in children with coexisting allergic diseases in the context of sex differences and to explore the behavioral profiles of these patients. We recruited a total of 103 children with atopic diseases and divided them into four groups: males with one allergic disease (MA1, n = 20), males with two or more allergic diseases (MA2, n = 26), females with one allergic disease (FA1, n = 30), and females with two or more allergic diseases (FA2, n = 27). We measured serum calcium levels using the colorimetric method and serum 25-OH vitamin D total levels using electrochemiluminescence immunoassay. We found that MA2 had significantly lower vitamin D levels than MA1 and FA2. The levels of IgE were negatively correlated with vitamin D in females, whereas the levels of IgE were not significantly correlated with vitamin D in males. Furthermore, serum IgE was significantly correlated with children's adaptive skills, and different sexes were associated with different aspects of adaptive skills. Our findings suggest a protective role of vitamin D in the development of one allergic disease against the coexistence of allergic diseases in males, as well as extend the evidence for sex differences in immunity by demonstrating a sex-different correlation between IgE and vitamin D and the relationship between IgE and children's adaptive skills.

07 Aug 2023·Microorganisms

Aspergillus nomiae and fumigatus Ameliorating the Hypoxic Stress Induced by Waterlogging through Ethylene Metabolism in Zea mays L.

Article

Author: Arif, Muhammad ; Rahman, Khalil Ur ; Ali, Kashmala ; Rauf, Mamoona

Transient and prolonged waterlogging stress (WS) stimulates ethylene (ET) generation in plants, but their reprogramming is critical in determining the plants' fate under WS, which can be combated by the application of symbiotically associated beneficial microbes that induce resistance to WS. The present research was rationalized to explore the potential of the newly isolated 1-aminocyclopropane-1-carboxylic acid (ACC) deaminase-producing fungal endophytic consortium of Aspergillus nomiae (MA1) and Aspergillus fumigatus (MA4) on maize growth promotion under WS. MA1 and MA4 were isolated from the seeds of Moringa oleifera L., which ably produced a sufficient amount of IAA, proline, phenols, and flavonoids. MA1 and MA4 proficiently colonized the root zone of maize (Zea mays L.). The symbiotic association of MA1 and MA4 promoted the growth response of maize compared with the non-inoculated plants under WS stress. Moreover, MA1- and MA4-inoculated maize plants enhanced the production of total soluble protein, sugar, lipids, phenolics, and flavonoids, with a reduction in proline content and H₂O₂ production. MA1- and MA4-inoculated maize plants showed an increase in the DPPH activity and antioxidant enzyme activities of CAT and POD, along with an increased level of hormonal content (GA₃ and IAA) and decreased ABA and ACC contents. Optimal stomatal activity in leaf tissue and adventitious root formation at the root/stem junction was increased in MA1- and MA4-inoculated maize plants, with reduced lysigenous aerenchyma formation, ratio of cortex-to-stele, water-filled cells, and cell gaps within roots; increased tight and round cells; and intact cortical cells without damage. MA1 and MA4 induced a reduction in deformed mesophyll cells, and deteriorated epidermal and vascular bundle cells, as well as swollen metaxylem, phloem, pith, and cortical area, in maize plants under WS compared with control. Moreover, the transcript abundance of ethylene-responsive gene ZmEREB180, responsible for the induction of the WS tolerance in maize, showed optimally reduced expression sufficient for induction in WS tolerance, in MA1- and MA4-inoculated maize plants under WS compared with the non-inoculated control. The existing research supported the use of MA1 and MA4 isolates for establishing the bipartite mutualistic symbiosis in maize to assuage the adverse effects of WS by optimizing ethylene production.

News (Medical) associated with Tasimelteon

01 Jul 2024

·www.prnewswire.com

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex

WASHINGTON, July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of Delaware (the "Court") denied the motions for judgment on the pleadings that were filed by Teva Pharmaceuticals USA, Inc. ("Teva") and Apotex Inc. and Apotex Corp. ("Apotex") and ordered that Vanda's HETLIOZ® patent lawsuit may proceed. Vanda brought this suit in December 2022, alleging patent infringement against Teva and Apotex (the "Defendants"). The Defendants moved for judgment on the pleadings in April 2023. On June 27, 2024, the Court denied the motions. The Court concluded that the issues of patentability were not the same as those resolved in prior patent-infringement litigation between the parties. It further concluded that the Defendants raised issues that require claim construction and fact development before the Court can resolve the case. Vanda intends to proceed with discovery in the case to continue pursuing its claims. Vanda will request relief from the Court that includes an order requiring the Defendants to discontinue marketing their generic versions of HETLIOZ® until the expiration of the patent-in-suit and enjoining them from the commercial manufacture, use, import, offer for sale and/or sale of these products. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit and follow us on X @vandapharma. About HETLIOZ® For full U.S. Prescribing Information for HETLIOZ®, including indication and Important Safety Information, visit . CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Various statements in this press release, including, but not limited to statements regarding Vanda's intentions to proceed with discovery in pursuit of its claims and to request relief from the Court, are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the results of Vanda's discovery and the Court's willingness to grant Vanda the relief that it seeks. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at . All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Corporate Contact: Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc. 202-734-3400 [email protected] Jim Golden / Jack Kelleher / Dan Moore Collected Strategies [email protected] SOURCE Vanda Pharmaceuticals Inc.

Patent Infringement

20 Jun 2024

·www.fiercepharma.com

Vanda rejects buyout offers, pans 'opportunistic attempts' at securing its shares at a discount

Vanda has rejected multiple buyout proposals and is proceeding with its prior plans, the company said in a statement. A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself. After receiving "unsolicited" buyout proposals from Michigan-based CDMO Future Pak and U.K. drugmaker Cycle Pharmaceuticals, Vanda's board concluded that both offers "substantially undervalue" the company. Vanda has rejected the proposals, the company said in a June 19 press release. Starting in February, Future Pak began submitting a series of proposals to acquire Vanda. In April, Future Pak revealed that it was willing to buy Vanda for $7.25 to $7.75 per share. The following month, Future Pak boosted its offer by floating contingent value rights worth up to $260 million tied to specific future commercial and regulatory accomplishments by Vanda. Early this month, Cycle Pharma got involved with a buyout offer of $8 per share, or $466 million in total. At the time, Vanda said it would "carefully review and evaluate the indication of interest" in the proposal. Now, Vanda is turning back both offers in favor of proceeding with its own plan. "The Vanda board again evaluated all aspects of Vanda's business against the unsolicited proposals and determined that the proposals are opportunistic attempts to purchase the company's shares at a discount to Vanda's intrinsic value," Vanda said in a statement. "The board's prior analysis of the company's clinical development pipeline, expanding commercial presence and significant cash balance remains unchanged." Vanda said its revenue base, cash position and efficient operations position the company "for significant long-term growth and value creation far in excess of the" other firms' offers. Vanda's share price has enjoyed a multi-month rally since a low of $3.47 in early February, rising to $6.50 last week. With the news that Vanda rejected the proposals, shares traded down by about 8% early Thursday. Vanda generated $192 million in 2023, a 24% decrease from the prior year as sleep disorder drug Hetlioz posted sharply lower sales thanks to U.S. generic competition. Seeking to regroup for a new phase of growth, Vanda recently acquired Ponvory, a former Johnson & Johnson multiple sclerosis drug, for $100 million. And its schizophrenia stalwart Fanapt won an expanded label to treat bipolar I disorder.

Acquisition

07 Jun 2024

·www.biospace.com

Vanda Gets $466M Unsolicited Offer from Cycle Amid Ongoing Row with FDA

Pictured: Boardroom overlooking a city/iStock, ismagilov Vanda Pharmaceuticals on Thursday confirmed that it has received an unsolicited and non-binding takeover offer from Cycle Pharmaceuticals for $8 per share, a price Vanda’s stock has not traded at since January 2023. Cycle in a separate announcement noted that its per-share offer represents a 63% premium to Vanda’s closing price on May 23, 2024, the day before Cycle submitted its takeover proposal, and a 58% premium to the biotech’s closing share price on Wednesday. The deal’s total cash consideration is $466 million. According to Cycle, its offer “delivers immediate, compelling and certain cash value for Vanda shareholders, with a highly attractive premium,” noting that the deal would also benefit patients given Cycle’s “proven commercial strategy in the U.S., a strong distribution footprint and an established track record of delivering medicines and individualized support to patients.” Cycle’s offer also trumps Future Pak’s revised takeover bid. Filed in May 2024, Future Pak’s new proposal was valued at $7.25 to $7.75 per share plus certain contingent value rights (CVR). Vanda previously turned down an initial proposal from Future Pak, which offered a similar per-share price range without the CVR. Vanda said on Thursday that its board of directors will “carefully review and determine” its course of action regarding Cycle’s offer. The company is staying mum on the further details of the deal and its interest in the offer, but has said that shareholders currently have no need to take any action. Cycle’s takeover offer comes as Vanda is engaged in a regulatory row with the FDA. In February 2024, the agency denied to approve Vanda’s supplemental New Drug Application (sNDA), which was seeking to use its oral drug Hetlioz (tasimelteon) to treat insomnia as characterized by difficulty with sleep initiation. At the time, Vanda said that “no deficiencies were disclosed by the FDA in the notification.” The biotech slammed the regulator’s rejection, saying that it “believes that the timing of the FDA’s communication is part of an ongoing violation of the Federal Food Drug, and Cosmetic Act (FDCA),” which requires the regulator to “either approval a new drug application or provide an opportunity for a hearing within 180 days after the filing of an application.” Vanda filed its sNDA on May 4, 2023, which means the FDA’s FDCA-mandated deadline was on October 31, 2023. “The FDA has not complied with the statute and has not timely approved the application or provided an opportunity for a hearing within the statutorily prescribed timeframe,” according to the biotech. In a rare move, the FDA on Friday released documentation detailing its reasons for rejecting Hetlioz and giving Vanda the option to seek a hearing. According to the regulator, the biotech’s application “does not provide substantial evidence of effectiveness for tasimelteon and does not demonstrate that the drug is safe for the treatment of insomnia.” Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

AcquisitionDrug Approval

100 Deals associated with Tasimelteon

External Link

KEGG	Wiki	ATC	Drug Bank
D09388	Tasimelteon	N05CH03	DB09071

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Sleep Initiation and Maintenance Disorders	US	Vanda Pharmaceuticals, Inc.	01 Dec 2020
Sleep Wake Disorders	US	Vanda Pharmaceuticals, Inc.	31 Jan 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Jet Lag Syndrome	NDA/BLA	US	Vanda Pharmaceuticals, Inc.	-
Autism Spectrum Disorder	Phase 3	US	Vanda Pharmaceuticals, Inc.	28 Jul 2021
Sleep Deprivation	Phase 3	US	Vanda Pharmaceuticals, Inc.	01 Sep 2015
Smith-Magenis Syndrome	Phase 3	US	Vanda Pharmaceuticals, Inc.	01 Sep 2015
Depressive Disorder, Major	Phase 3	US	Vanda Pharmaceuticals, Inc.	01 Sep 2011
Sleep Disorders, Circadian Rhythm	Phase 3	US	Vanda Pharmaceuticals, Inc.	01 Aug 2010
Sleep Disorders, Circadian Rhythm	Phase 3	DE	Vanda Pharmaceuticals, Inc.	01 Aug 2010
Pervasive child development disorders	Phase 2	US	Vanda Pharmaceuticals, Inc.	16 Sep 2021
REM Sleep Behavior Disorder	Phase 1	US	Vanda Pharmaceuticals, Inc.	30 Sep 2023
Renal Insufficiency	Phase 1	US	Vanda Pharmaceuticals, Inc.	01 Feb 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03373201 (CTgov)	Phase 3	Jet Lag Syndrome	320	Placebo (Placebo)	udvruujdoc(cjdzorfizp) = lbwjmgiyee jfsgbmagxa (kdvnffigtn, bdudkwjgru - pzowcvnziy) View more	-	15 Sep 2023
				Tasimelteon (Tasimelteon)	udvruujdoc(cjdzorfizp) = edzqyywiuk jfsgbmagxa (kdvnffigtn, xucmwfqrja - tenvdgsosa) View more
NCT03291041 (JET, Pubmed) Manual	Phase 2	Jet Lag Syndrome	25	tasimelteon	kbffbkqagg(orscsslysw): difference = 131	Positive	15 Sep 2022
				Placebo
NCT03291041 (JET, CTgov)	Phase 2	Jet Lag Syndrome	25	Tasimelteon (Tasimelteon)	lpsgmameli(efiawuignw) = jyvhhiqyob ejrftizylx (xjojfnjhtq, zkftnwkrzn - smbjisdntp) View more	-	03 Nov 2021
				placebo (Placebo)	lpsgmameli(efiawuignw) = cpxagjmwcj ejrftizylx (xjojfnjhtq, bzegyvtjlm - hoyrvrgdox) View more
WSC2019	Not Applicable	-	318	Tasimelteon	ndjwhgwuun(jywfgsxgbi) = sbddxspmsb gdfkhjupdy (ozkmvdpuxl )	Positive	20 Sep 2019
NCT01163032 (SET, Pubmed \| Lancet) Manual	Phase 3	Sleep Disorders, Circadian Rhythm	84	tasimelteon	vzhefsqttt(apatvrjbcn) = dyqazybhdz donpphqrrx (wtclnghhlq ) View more	Positive	31 Oct 2015
				Placebo	vzhefsqttt(apatvrjbcn) = hrwbsqdbui donpphqrrx (wtclnghhlq ) View more
NCT01428661 (MAGELLAN, CTgov)	Phase 2/3	Depressive Disorder, Major	507	tasimelteon (Tasimelteon)	xnpztmwwwp(penrsqbfac) = zmyybloepm ymofurztyf (wttjzsoryg, euaurtrgge - repwrhnpap) View more	-	19 Jun 2015
				placebo (Placebo)	xnpztmwwwp(penrsqbfac) = rrqrrtteec ymofurztyf (wttjzsoryg, aibuxzfkxz - jvnarlmagb) View more
NCT01163032 (CTgov)	Phase 3	Sleep Disorders, Circadian Rhythm	136	tasimelteon (Tasimelteon (Randomized))	ivoduioijd(tahjxouzpt) = pqdfnhahck rwjaxcipee (cswjucklsr, dcajqatvdb - amkogitfcs) View more	-	16 Oct 2014
				Placebo (Placebo (Randomized))	ivoduioijd(tahjxouzpt) = lnlbwptliq rwjaxcipee (cswjucklsr, iumrnzcerm - ndpthhrdzy) View more
NCT00548340 (CTgov)	Phase 3	Sleep Initiation and Maintenance Disorders	322	VEC-162 20 mg (VEC-162 20 mg)	mibmmxzogw(hdyhtphiak) = louzvyqayo fdhbijnuja (nmesmirkww, tqypnpjqcf - bbgoqzrcro) View more	-	15 Oct 2014
				VEC-162 50 mg (VEC-162 50 mg)	mibmmxzogw(hdyhtphiak) = gcdduiaald fdhbijnuja (nmesmirkww, eqavxcgbvm - xydfexgeuf) View more
NCT00291187 (CTgov)	Phase 3	Sleep Initiation and Maintenance Disorders	411	placebo	firfzdnrdg(xotnsdsmpe) = dpsjtfhnhk dgvvgkogtv (lxvdmgxbpq, zcafnbawzq - uftxuaqkgv) View more	-	15 Oct 2014
NCT01430754 (RESET, CTgov)	Phase 3	Sleep Disorders, Circadian Rhythm	20	tasimelteon (Tasimelteon)	jdxdqwyflo(sezstnffmq) = mvpvaqomhn aknkythyud (fvfptxypyv, fmprwtzgtd - rgpsfqubxo) View more	-	10 Oct 2014
				placebo (Placebo)	jdxdqwyflo(sezstnffmq) = uwfilxruco aknkythyud (fvfptxypyv, wejxgwbqmh - mymnbgkxnp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis